This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

| More on:
Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be edging lower on Monday but that hasn't stopped one ASX All Ords stock from rocketing.

In morning trade, the Capitol Health Ltd (ASX: CAJ) share price is up 20% to 29.5 cents.

Why is this ASX All Ords stock rocketing?

Investors have been scrambling to buy the diagnostic imaging modalities provider's shares this morning after it accepted a merger offer from rival Integral Diagnostics Ltd (ASX: IDX).

According to the release, the two parties have entered into a process and exclusivity deed that will see Integral Diagnostics acquire 100% of Capitol Health via a scheme of arrangement.

The offer that was tabled was an implied exchange ratio of 0.12849 Integral Diagnostics shares for every Capitol Health share. Based on Friday's close prices, this equates to an offer of 32.6 cents per share, which represents a 33% premium.

Capitol Health's chair, Andrew Demetriou, commented:

The Indicative Proposal reflects attractive value for Capitol shareholders and the Board has determined that it is in the best interests of shareholders to engage with Integral.

Capitol Health advised that that each director intends to recommend shareholders to vote in favour of the proposed transaction. This is subject to entry into the implementation deed, the absence of a superior proposal, and the independent expert's report.

Not the first offer

The release notes that this indicative proposal was not the first. It follows an unsolicited approach from Integral Diagnostics in late March regarding a potential combination.

However, while that was not accepted, the ASX All Ords stock's board decided that it was in the best interests of shareholders to engage with Integral Diagnostics and provide non-public information on a confidential and non-exclusive basis to conduct a two-way value based due diligence process.

Following the conclusion of the process, Integral Diagnostics submitted the improved indicative proposal, which has now been accepted.

The ASX All Ords stock's managing director, Justin Walter, commented:

Today's proposed merger announcement with Integral, represents an exciting opportunity for all our valued radiologists, technicians, and staff to be part of Australia's largest pure-play publicly listed imaging company.

This opportunity is a result of their dedicated hard work, particularly over the last five years. The merger will create further value for our shareholders by realising significant benefits through scale, enhanced internal capability, and organic growth.

All underpinned by market leading clinical standards and service to our referrers and their patients.

As things stand, Capitol Health shareholders do not need to take any action regarding the proposal. However, the company warned that it cannot be certain that the proposal will result in a binding transaction.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Lab technician analyses a sample in a laboratory for a clinical trial
Earnings Results

Monash IVF share price plunges 18% on lower FY26 profit guidance and no dividend

Revenue and EBITDA increased in FY25 but the outlook is gloomy and no final dividend will be paid.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

Why is everyone talking about CSL shares?

CSL suffered a ‘brutal selloff’ this week.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Healthcare Shares

Why this ASX 200 stock could be a bargain buy after crashing 13%

Bell Potter thinks that a buying opportunity could have opened up for investors.

Read more »

A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today
Healthcare Shares

A $115 million growth opportunity!? Is this ASX 200 stock about to skyrocket?

The company's share price has jumped 141.67% over the past 12 months.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Healthcare Shares

Is the CSL share price dirt cheap after crashing this week?

Is this beaten down biotech cheap? Let's find out.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Why Macquarie says the HUGE sell-off in CSL shares is way overdone

Macquarie forecasts a big rebound is coming for CSL shares. But why?

Read more »

A sole trekker climbs a steep snowy mountain.
Healthcare Shares

This ASX healthcare stock could be a buy low bargain

After a rough 12 months, is this a buy low target?

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Broker Notes

Does Macquarie rate Pro Medicus shares a buy after they surged again on FY25 results?

Macquarie delivers its verdict on the 12-month outlook for Pro Medicus shares.

Read more »